These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 36593066)
41. The Thousand Faces of Malignant Melanoma: A Systematic Review of the Primary Malignant Melanoma of the Esophagus. Cazzato G; Cascardi E; Colagrande A; Lettini T; Resta L; Bizzoca C; Arezzo F; Loizzi V; Dellino M; Cormio G; Casatta N; Lupo C; Scillimati A; Scacco S; Parente P; Lospalluti L; Ingravallo G Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954389 [TBL] [Abstract][Full Text] [Related]
42. The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance and prognostic value: a study of 89 consecutive cases. Ren Y; Lv Q; Yue W; Liu B; Zou Z Melanoma Res; 2020 Feb; 30(1):85-101. PubMed ID: 31095042 [TBL] [Abstract][Full Text] [Related]
43. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade. Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M Front Immunol; 2022; 13():794684. PubMed ID: 35720386 [TBL] [Abstract][Full Text] [Related]
44. Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides. Ueda Y; Shimizu K; Itoh T; Fuji N; Naito K; Shiozaki A; Yamamoto Y; Shimizu T; Iwamoto A; Tamai H; Yamagishi H Jpn J Clin Oncol; 2007 Feb; 37(2):140-5. PubMed ID: 17255158 [TBL] [Abstract][Full Text] [Related]
45. A case of primary malignant melanoma of the esophagus with a widely expanded surface area. Nakamura K; Urabe Y; Oka S; Ito M; Kotachi T; Ninomiya Y; Boda T; Hiyama T; Emi M; Hamai Y; Shiroma N; Tanaka S; Chayama K Clin J Gastroenterol; 2019 Oct; 12(5):424-428. PubMed ID: 30887427 [TBL] [Abstract][Full Text] [Related]
46. Primary amelanotic malignant melanoma of the esophagus: a case report. Koga N; Kubo N; Saeki H; Sasaki S; Jogo T; Hirose K; Nakashima Y; Oki E; Koga Y; Oda Y; Oiwa H; Oiwa T; Maehara Y Surg Case Rep; 2019 Jan; 5(1):4. PubMed ID: 30635729 [TBL] [Abstract][Full Text] [Related]
47. A long-term survivor with esophageal melanoma and pulmonary metastasis after single-stage esophagectomy and lobectomy: Case report and literature review. Zhao T; Kong FW; Wang H; Liu D; Wang CY; Luo JH; Zhang M; Wu WB Medicine (Baltimore); 2017 May; 96(21):e7003. PubMed ID: 28538413 [TBL] [Abstract][Full Text] [Related]
48. Radical Resection in an Era of Immune Therapy for Primary Esophageal Melanoma. Williams E; Bolger JC; Darling G Ann Thorac Surg; 2022 Dec; 114(6):e423-e425. PubMed ID: 35218701 [TBL] [Abstract][Full Text] [Related]
49. Primary malignant melanoma of esophagus following chemoradiotherapy for esophageal squamous cell carcinoma: report of a case. Imai S; Suzuki A; Yamamoto Y; Koyama M; Sugiyama S; Kitazawa M; Miyagawa Y; Miyagawa S Clin J Gastroenterol; 2017 Aug; 10(4):336-341. PubMed ID: 28550655 [TBL] [Abstract][Full Text] [Related]
50. Primary malignant melanoma of the esophagus treated with subtotal esophagectomy: a case report. Kuwabara S; Ebihara Y; Nakanishi Y; Asano T; Noji T; Kurashima Y; Murakami S; Nakamura T; Tsuchikawa T; Okamura K; Shichinohe T; Hirano S BMC Surg; 2017 Dec; 17(1):122. PubMed ID: 29197361 [TBL] [Abstract][Full Text] [Related]
51. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557 [TBL] [Abstract][Full Text] [Related]
52. The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma. Ma VT; Daignault-Newton S; Waninger JJ; Journey S; Chopra Z; Tezel A; Redman BG; Fecher LA; Green MD; Alva AS; Lao CD Pigment Cell Melanoma Res; 2021 May; 34(3):629-640. PubMed ID: 33128316 [TBL] [Abstract][Full Text] [Related]